UBS Group AG - 4D MOLECULAR THERAPEUTICS IN ownership

4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 89 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
UBS Group AG ownership history of 4D MOLECULAR THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$571,539
-41.3%
44,897
-16.6%
0.00%
Q2 2023$973,070
+8.0%
53,850
+2.8%
0.00%
Q1 2023$900,739
-0.4%
52,399
+28.7%
0.00%
Q4 2022$904,56940,728
+116265.7%
0.00%
Q2 2022$0
-100.0%
35
-100.0%
0.00%
Q1 2022$1,063,000
-30.2%
70,234
+1.3%
0.00%
Q4 2021$1,522,000
+4376.5%
69,350
+5421.5%
0.00%
Q3 2021$34,000
-96.2%
1,256
-93.9%
0.00%
Q1 2021$893,00020,5920.00%
Other shareholders
4D MOLECULAR THERAPEUTICS IN shareholders Q3 2022
NameSharesValueWeighting ↓
VR Adviser, LLC 3,000,000$38,190,0004.02%
Casdin Capital, LLC 1,033,811$13,160,4141.46%
BVF INC/IL 4,007,413$51,014,3671.38%
Deep Track Capital, LP 2,778,107$35,365,3021.36%
Opaleye Management Inc. 308,500$3,927,2051.28%
Eagle Health Investments LP 437,911$5,574,6071.23%
Novo Holdings A/S 1,200,000$15,276,0001.13%
RA Capital Management 4,163,211$52,997,6761.04%
VIKING GLOBAL INVESTORS LP 4,787,914$60,950,1450.25%
HighVista Strategies LLC 33,419$425,4240.20%
View complete list of 4D MOLECULAR THERAPEUTICS IN shareholders